Literature DB >> 27313714

Complete response to abdominal bulky lymph node recurrence in an esophageal cancer patient treated with S-1 monotherapy: A case report.

Atsuto Katano1, Hideomi Yamashita1, Kae Okuma1, Keiichi Nakagawa1.   

Abstract

Esophageal cancer is a highly lethal malignancy of the upper gastrointestinal tract. The recurrence of the cancer indicates a poor prognosis, and even salvage therapy using multi-agent combination chemotherapy, which is considered more effective than single-agent chemotherapy, is not able to achieve a sufficient response. The present study reports the case of a 74-year-old male who presented to a local hospital with dysphagia in February 2006. Upon radiographic and pathological examination, the patient was diagnosed with squamous cell carcinoma of esophagus that was clinically staged as T3N1M1. The patient was referred to the University of Tokyo Hospital (Tokyo, Japan) for concurrent chemoradiotherapy using a radiation dose of 50.4 Gy in 28 fractions, and subsequently achieved a complete response (CR). At 8 years after the initial diagnosis and subsequent treatment, the patient presented with abdominal swollen lymph nodes that were 38 mm and 22 mm in diameter. Recurrent metastasis was diagnosed. A single-agent regimen was selected due to the patient's poor performance status. This consisted of 2 cycles of oral S-1 administration twice a day for 2 consecutive weeks, followed by 2 weeks of rest (80 mg/day for 14 days/cycle). A CR was achieved following the use of S-1 administration as salvage therapy. The patient exhibited no signs of recurrence subsequent to 9 months of follow-up. Overall, the present study reports that S-1 administration shows marked effectiveness in the treatment of huge recurrent lesions. S-1 is considered as a good treatment option in patients with poor a performance status who require salvage therapy.

Entities:  

Keywords:  S-1; esophageal cancer; recurrence; salvage therapy; squamous cell carcinoma

Year:  2016        PMID: 27313714      PMCID: PMC4888222          DOI: 10.3892/ol.2016.4462

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  13 in total

Review 1.  Esophageal cancer.

Authors:  Peter C Enzinger; Robert J Mayer
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

2.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Alicia F C Okines; Sue Ashley
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

3.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.

Authors:  T Shirasaka; Y Shimamato; H Ohshimo; M Yamaguchi; T Kato; K Yonekura; M Fukushima
Journal:  Anticancer Drugs       Date:  1996-07       Impact factor: 2.248

Review 4.  [A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].

Authors:  Noriaki Kanamori; Masashi Fujii; Toru Takahashi; Kazuhiko Wakabayashi; Mitsugu Kochi; Keio Sou; Tadatoshi Takayama
Journal:  Gan To Kagaku Ryoho       Date:  2007-09

5.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

6.  S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.

Authors:  Yasunori Akutsu; Tsuguaki Kono; Masaya Uesato; Isamu Hoshino; Kazuo Narushima; Toshiharu Hanaoka; Toru Tochigi; Yoshihide Semba; Wei Qin; Hisahiro Matsubara
Journal:  Oncology       Date:  2013-04-12       Impact factor: 2.935

7.  Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial.

Authors:  T Iizuka; T Kakegawa; H Ide; N Ando; H Watanabe; O Tanaka; I Takagi; K Isono; K Ishida; M Arimori
Journal:  Jpn J Clin Oncol       Date:  1992-06       Impact factor: 3.019

Review 8.  Epidemiology of esophageal cancer.

Authors:  Yuwei Zhang
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

9.  Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma.

Authors:  L E Quint; L M Hepburn; I R Francis; R I Whyte; M B Orringer
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

10.  Esophageal cancer chemotherapy: recent advances.

Authors:  David H Ilson
Journal:  Gastrointest Cancer Res       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.